Li Lanjuan: Pioneer of Epidemiology

Li Lanjuan is a Chinese epidemiologist, a member of the High-level Expert Group of the NHC, and an academician of the Chinese Academy of Engineering. She has undertaken the tasks of diagnosis, treatment and research for infectious diseases such as the SARS, the hand-foot-and-mouth disease, post-quake epidemics and the H1N1 flu virus. She has made many groundbreaking achievements in the prevention and control of the H7N9 flu virus, and has contributed greatly to the diagnosis and treatment of infectious diseases in China.

Amid the outbreak of the novel coronavirus, the 73-year-old Li Lanjuan led a medical team to Wuhan and worked day and night at the designated hospitals for treating severe cases. She educated the public about the virus, discussed the guidelines for diagnosis and treatment with other medical workers, and slept only three hours a day. 

Three days after arriving in Wuhan, Li's team announced an important research achievement, indicating that Arbidol and Darunavir could effectively curb the virus. Arbidol was later added in the Guidelines on the Novel Coronavirus-Infected Pneumonia Diagnosis and Treatment (Provisional 6th Edition).

李蘭娟：國家傳染病重點學科帶頭人

李蘭娟，中國傳染病學專家，國家衛生健康委高級別專家組成員，中國工程院院士。曾承擔SARS、手足口病、地震災后防疫、甲型H1N1等傳染病診治研究任務，尤其在防控人感染H7N9禽流感救治研究中取得眾多原創性成果，為中國傳染病診治做出了重大貢獻。

在新冠肺炎疫情蔓延之際， 73歲的李蘭娟率醫療隊抵達武漢。在收治危重患者的定點醫院，李蘭娟不分晝夜地工作，向公眾普及病毒知識、與醫護人員商討診療方案，每天只睡3個小時。在到達武漢后的第3天，李蘭娟院士團隊發布了重大研究成果，稱阿比朵爾、達蘆那韋兩款藥物能夠有效抑制新型冠狀病毒。隨后，阿比朵爾列入《新型冠狀病毒肺炎診療方案（試行第六版）》。